CD274 and non-small cell lung carcinoma: In another multicenter retrospective study of non-small cell lung cancer (NSCLC), 144 patients who had been treated with anti-PD(L)1 antibodies and who had interrupted their ICIs therapy due to toxicity or disease progression had an ORR and DCR of 15.9% and 47.2%, respectively, after re-administration of anti-PD(L)1 antibody (7).